1
|
Yan M, Bustos SS, Kuruoglu D, Ciudad P, Forte AJ, Kim EA, Del Corral G, Manrique OJ. Systematic review of fertility preservation options in transgender patients: a guide for plastic surgeons. ANNALS OF TRANSLATIONAL MEDICINE 2021; 9:613. [PMID: 33987311 DOI: 10.21037/atm-20-4523] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Transgender patients often desire to have biological children. However, their reproductive potential is often negatively impacted by gender affirming surgery (GAS) such as gender confirmation surgery (bottom surgery) and medical hormone therapy. Therefore, counselling patients on fertility preservation options before initiating gender-affirming treatments is prudent to avoid reducing their reproductive potential. A systematic review of English, Spanish, Chinese, French and Turkish languages from 2000 to December 23rd, 2019, using the preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) guidelines, was conducted. The search strategy was designed and conducted by an experienced librarian with input from the study's principle investigator. Fifteen articles that report outcomes of fertility preservation options in transgenders were included. Eight articles described options for transgender women, six reported options for transgender men and one included both transgender women and transgender men. Semen cryopreservation and oocyte cryopreservation are the most common and available methods for fertility preservation in transgenders. Physician awareness of fertility preservation options in transgender patients is crucial to ensure informed discussions regarding reproductive options in the early phase of transition.
Collapse
Affiliation(s)
- Maria Yan
- Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota, USA
| | - Samyd S Bustos
- Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota, USA.,Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Doga Kuruoglu
- Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota, USA.,Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA
| | - Pedro Ciudad
- Department of Plastic, Reconstructive and Burn Surgery, Arzobispo Loayza National Hospital, Lima, Peru
| | - Antonio J Forte
- Division of Plastic and Reconstructive Surgery, Mayo Clinic Florida Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Jacksonville, USA
| | - Esther A Kim
- Division of Plastic and Reconstructive Surgery, University of California, San Francisco, California, USA
| | - Gabriel Del Corral
- Department of Plastic Surgery, Medstar Georgetown University Hospital, Washington, District of Columbia, USA
| | - Oscar J Manrique
- Division of Plastic and Reconstructive Surgery, Mayo Clinic, Rochester, Minnesota, USA.,Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA
| |
Collapse
|
2
|
Semen Parameters Among Transgender Women With a History of Hormonal Treatment. Urology 2019; 124:136-141. [DOI: 10.1016/j.urology.2018.10.005] [Citation(s) in RCA: 56] [Impact Index Per Article: 11.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2018] [Revised: 09/09/2018] [Accepted: 10/02/2018] [Indexed: 11/17/2022]
|
3
|
Wahab F, Atika B, Shahab M, Behr R. Kisspeptin signalling in the physiology and pathophysiology of the urogenital system. Nat Rev Urol 2015; 13:21-32. [DOI: 10.1038/nrurol.2015.277] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
|
4
|
Jiang S, Hong M, Su S, Song M, Tian Y, Cui P, Song S, Wang Y, Li F, Fang F. Effect of active immunization against GnRH-I on the reproductive function in cat. Anim Sci J 2015; 86:747-54. [DOI: 10.1111/asj.12355] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2013] [Accepted: 10/03/2014] [Indexed: 11/29/2022]
Affiliation(s)
- Shudong Jiang
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Meizhen Hong
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Shiping Su
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Min Song
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Yuan Tian
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Pei Cui
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Shuang Song
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Yaoyao Wang
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
| | - Fubao Li
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
- Anhui Provincial Laboratory for Local Livestock and Poultry Genetic Resource Conservation and Bio-Breeding; Hefei Anhui China
- Engineering Research Center of Reproduction and breeding in Sheep of Anhui Province; Hefei Anhui China
| | - Fugui Fang
- Anhui Provincial Laboratory of Animal Genetic Resources Protection and Breeding; College of Animal Sciences and Technology; Anhui Agricultural University; Hefei Anhui China
- Anhui Provincial Laboratory for Local Livestock and Poultry Genetic Resource Conservation and Bio-Breeding; Hefei Anhui China
- Engineering Research Center of Reproduction and breeding in Sheep of Anhui Province; Hefei Anhui China
| |
Collapse
|
5
|
Thompson EL, Amber V, Stamp GWH, Patterson M, Curtis AE, Cooke JH, Appleby GF, Dhillo WS, Ghatei MA, Bloom SR, Murphy KG. Kisspeptin-54 at high doses acutely induces testicular degeneration in adult male rats via central mechanisms. Br J Pharmacol 2009; 156:609-25. [PMID: 19226253 PMCID: PMC2697701 DOI: 10.1111/j.1476-5381.2008.00061.x] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2008] [Revised: 10/07/2008] [Accepted: 10/10/2008] [Indexed: 11/29/2022] Open
Abstract
BACKGROUND AND PURPOSE The kisspeptins are critical regulators of reproduction and a therapeutic target for reproductive disease. Intracerebroventricular (i.c.v.) or peripheral injection of kisspeptin potently stimulates the hypothalamic-pituitary gonadal (HPG) axis via gonadotrophin-releasing hormone (GnRH). However, little is known regarding the effects of kisspeptin administration on testicular function. We investigated the mechanism(s) of kisspeptin-induced testicular degeneration in the rat. EXPERIMENTAL APPROACH Kisspeptin-54 (50 nmol.day(-1)) was continuously administered subcutaneously (6 h to 3 days) to male Wistar rats and reproductive hormones and testicular histology analysed. We also investigated the effects of a single subcutaneous injection of 0.5, 5 or 50 nmol kisspeptin-54. In order to determine whether the testicular degeneration observed is peripherally or centrally mediated, we investigated effects of i.c.v. injections of 5 nmol kisspeptin-54 and pre-administered a GnRH-receptor antagonist (cetrorelix) to rats peripherally treated with kisspeptin-54. KEY RESULTS Continuous subcutaneous administration of kisspeptin-54 caused testicular degeneration after only 12 h, when gonadotrophins were still markedly raised, suggesting that the degeneration is independent of the desensitization of the HPG axis to kisspeptin-54. Furthermore, a single subcutaneous injection of kisspeptin-54 caused dose-dependent testicular degeneration. Continuous kisspeptin-54 administration is thus not required to cause testicular degeneration. Pretreatment with cetrorelix blocked kisspeptin-induced testicular degeneration, and a single i.c.v. injection of kisspeptin-54 caused testicular degeneration, suggesting it is GnRH-mediated. CONCLUSIONS AND IMPLICATIONS Kisspeptin-induced testicular degeneration appears to be centrally mediated, and result from acute hyper-stimulation of the HPG axis. Doses must be carefully considered if kisspeptin is to be used therapeutically.
Collapse
Affiliation(s)
- EL Thompson
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - V Amber
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - GWH Stamp
- Department of Histopathology, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - M Patterson
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - AE Curtis
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - JH Cooke
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - GF Appleby
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - WS Dhillo
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - MA Ghatei
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - SR Bloom
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| | - KG Murphy
- Department of Investigative Medicine, Hammersmith Hospital, Imperial College LondonLondon, UK
| |
Collapse
|
6
|
Thompson EL, Murphy KG, Patterson M, Bewick GA, Stamp GWH, Curtis AE, Cooke JH, Jethwa PH, Todd JF, Ghatei MA, Bloom SR. Chronic subcutaneous administration of kisspeptin-54 causes testicular degeneration in adult male rats. Am J Physiol Endocrinol Metab 2006; 291:E1074-82. [PMID: 16787965 DOI: 10.1152/ajpendo.00040.2006] [Citation(s) in RCA: 108] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The kisspeptins are KiSS-1 gene-derived peptides that signal through the G protein-coupled receptor-54 (GPR54) and have recently been shown to be critical regulators of reproduction. Acute intracerebroventricular or peripheral administration of kisspeptin stimulates the hypothalamic-pituitary-gonadal (HPG) axis. This effect is thought to be mediated via the hypothalamic gonadotropin-releasing hormone (GnRH) system. Chronic administration of GnRH agonists paradoxically suppresses the HPG axis after an initial agonistic stimulation. We investigated the effects of continuous peripheral kisspeptin administration in male rats by use of Alzet minipumps. Initially we compared the effects of acute subcutaneous administration of kisspeptin-10, -14, and -54 on the HPG axis. Kisspeptin-54 produced the greatest increase in plasma LH and total testosterone at 60 min postinjection and was used in the subsequent continuous administration experiments. Chronic subcutaneous long-term administration of 50 nmol kisspeptin-54/day for 13 days decreased testicular weight. Histological examination showed degeneration of the seminiferous tubules associated with a significant decrease in the circulating levels of the testes-derived hormone, inhibin B. Plasma free and total testosterone were also lower, although these changes did not reach statistical significance. Further studies examined the effects of shorter periods of continuous kisspeptin administration. Subcutaneous administration of 50 nmol kisspeptin-54 for 1 day increased plasma LH and testosterone. This effect was lost after 2 days of administration, suggesting a downregulation of the HPG axis response to kisspeptin following continuous administration. These findings indicate that kisspeptin may provide a novel tool for the manipulation of the HPG axis and spermatogenesis.
Collapse
Affiliation(s)
- Emily L Thompson
- Department of Metabolic Medicine, Hammersmith Hospital, Imperial College London, London, United Kingdom
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
|
8
|
Abstract
Leuprorelin has demonstrated effectiveness comparable to orchiectomy and oral diethylstilboestrol for the palliation of advanced prostate cancer. Unlike orchiectomy, leuprorelin's effects are reversible; also leuprorelin is not associated with the cardiovascular or thromboembolic adverse effects of oestrogens. For these reasons, leuprorelin has been widely used as an alternative to surgical castration or to oestrogens in the treatment of metastatic prostate cancer. Sustained-release leuprorelin microsphere formulations have been developed which exhibit zero order release of active drug from the injection site, such that in the United States the 7.5 mg dosage strength is recommended to be administered once a month and the 22.5 mg dosage strength once every three months. Although most patients will have suppressed release of pituitary luteinizing hormone by the third or fourth week after the first dose of depot leuprorelin, 4-5% of treated patients have been reported to have delayed responses, taking many more weeks or months to respond. A transient biochemical hormone escape has also been reported, although worsening of clinical symptoms has not accompanied the elevation of serum testosterone levels during treatment. Usually, leuprorelin is initiated as monotherapy when patients with advanced prostate cancer become symptomatic. However, newer studies of combination therapy of luteinizing hormone releasing hormone analogs with antiandrogens suggest that early initiation of therapy, at the time of diagnosis of advanced disease, may be beneficial, particularly in a subgroup of patients with small volume disease and good performance status. Leuprorelin is also undergoing evaluation as neoadjuvant therapy prior to radical prostatectomy for localized prostate cancer. Preliminary studies suggest that neoadjuvant leuprorelin in combination with an antiandrogen may be effective in downstaging prostate tumours. Leuprorelin commonly produces several adverse effects: hot flashes, decreased libido and impotence, and tumour flare.
Collapse
|
9
|
Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48:930-67. [PMID: 7533699 DOI: 10.2165/00003495-199448060-00008] [Citation(s) in RCA: 105] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Leuprorelin (leuprolide acetate) is a gonadotrophin-releasing hormone (GnRH) analogue used to treat a wide range of sex hormone-related disorders including advanced prostatic cancer, endometriosis and precocious puberty. It acts primarily on the anterior pituitary, inducing a transient early rise in gonadotrophin release. With continued use, leuprorelin causes pituitary desensitisation and/or down-regulation, leading to suppressed circulating levels of gonadotrophins and sex hormones. Clinical trials in men with advanced prostatic cancer demonstrate that leuprorelin (usually monthly depot injections of 3.75 or 7.5 mg) is less likely to cause serious adverse cardiovascular effects than diethylstilbestrol, and has comparable efficacy to bilateral orchiectomy or other GnRH analogues. Therefore, the choice between leuprorelin and orchiectomy may be made on the basis of the patient's treatment preference, along with specific patient characteristics and cost implications. Monthly intramuscular or subcutaneous administration of depot leuprorelin 3.75 mg was superior to placebo, and comparable to oral danazol 800 mg/day or intranasal buserelin 900 micrograms/day, in achieving objective and subjective responses in women with endometriosis. Thus, leuprorelin is an effective alternative to other treatments for women with endometriosis, but the recommended duration of its use in this clinical setting is limited to 6 months because it reduces bone mineral density. In children with central precocious puberty, leuprorelin (usually monthly intramuscular or subcutaneous injections of depot leuprorelin 3.75 to 15mg) decreases mean growth velocity and signs of sexual maturation and increases predicted adult height compared with baseline measurements. Although effects on final adult height are predicted from available data and require confirmation in long term follow-up studies, the absence of effective alternatives to GnRH analogues makes leuprorelin a first-line therapy for children with this rare disease. In women with uterine leiomyomata, monthly intramuscular administration of depot leuprorelin 3.75 mg for 6 months markedly reduces uterine volume and fibroid-related symptoms, but, as with other GnRH analogues, these effects dissipate following discontinuation of the drug. As adjuvant therapy in women undergoing in vitro fertilisation or gamete intrafallopian transfer, leuprorelin (usually 0.5 to 1 mg/day subcutaneously) reduces the risk of cancelled cycles for oocyte retrieval by preventing premature luteinisation. While some studies demonstrate an improvement in intermediate end-points such as increased number of mature oocytes retrieved and embryos available for transfer, a significant effect has not been demonstrated on the rate of live births per stimulated cycle.(ABSTRACT TRUNCATED AT 400 WORDS)
Collapse
Affiliation(s)
- G L Plosker
- Adis International Limited, Auckland, New Zealand
| | | |
Collapse
|
10
|
Affiliation(s)
- F C Wu
- MRC Reproductive Biology Unit, Edinburgh, UK
| |
Collapse
|
11
|
Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate. UROLOGICAL RESEARCH 1988; 16:315-9. [PMID: 2972102 DOI: 10.1007/bf00263642] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The effects of long term GnRH treatment with the biodegradable depot formulation of ICI 118.630 on hormone levels and spermatogenesis were investigated in 18 males with advanced prostate cancer. Plasma levels of FSH, LH, testosterone, DHEA-S and SHBG were monitored at regular intervals. The drug suppressed FSH, LH and testosterone significantly and did not affect DHEA-S and SHBG plasma levels. Tissue specimens for histologic assessment and quantitative analysis of germinal cell types were obtained at secondary orchidectomy in 16 patients immediately following GnRH analogue treatment. Germinal cell maturation was arrested at the spermatogonial stage. In two patients discontinuing treatment histologic assessment of secondary orchidectomy specimens 9 and 10 months after the last GnRH analogue depot injection resulted in germinal cell maturation to late spermatids in part of the tubule cross sections. These results indicate that long term administration of the GnRH analogue fails to produce complete testicular sclerosis and spermatogenic arrest might be reversible.
Collapse
|
12
|
Abstract
Analogs of GnRH constitute a new category of drugs available for the treatment of advanced prostatic cancer. The efficacy and safety of GnRH analogs in the treatment of this disease is now well established. These compounds represent an important alternative therapy for advanced prostatic cancer patients who do not wish to undergo orchiectomy or for whom DES is not tolerable because of the risk of cardiovascular complications. The advent of the monthly depot form of these drugs will make treatment more convenient and less invasive and will enhance patient compliance.
Collapse
|
13
|
Namiki M, Nonomura N, Nakamura M, Okuyama A, Sonoda T, Nishimune Y, Matsumoto K. Effects of a gonadotropin-releasing hormone agonist analog (ICI 118630) on endocrine functions of human testis in vivo and in vitro. Fertil Steril 1987; 48:1012-7. [PMID: 2960563 DOI: 10.1016/s0015-0282(16)59601-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Six prostatic cancer patients were treated with a gonadotropin-releasing hormone agonist analog (ICI 118630, ICI Pharmaceutical Division, Macclesfield, England) for 4 weeks, and serum testosterone (T) had fallen to the castration level in all patients. Subsequently, three of the patients were orchiectomized. There were no significant differences in follicle-stimulating hormone (FSH) and human chorionic gonadotropin (hCG) receptors between the testes treated with ICI 118630 and testes obtained from untreated prostatic cancer patients. In the other three patients, testicular responsiveness evaluated using hCG stimulation was similar before and after 4 weeks of treatment. In vitro studies testes removed from untreated prostatic cancer patients were cultured in a medium with or without ICI 118630 for 5 days. There were no significant differences in FSH and hCG receptors and T production between the two groups. In conclusion, ICI 118630 had no direct inhibitory effect on human testes.
Collapse
Affiliation(s)
- M Namiki
- Department of Urology, Osaka University Medical School, Japan
| | | | | | | | | | | | | |
Collapse
|
14
|
Hadziselimović F, Senn E, Bandhauer K. Effect of treatment with chronic gonadotropin releasing hormone agonist on human testis. J Urol 1987; 138:1048-50. [PMID: 3116284 DOI: 10.1016/s0022-5347(17)43497-5] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
Abstract
We removed and examined 24 testes from 12 patients with metastatic carcinoma (stages C2 and D2) of the prostate who had been treated previously with either the gonadotropin releasing hormone analogue buserelin alone or combined buserelin and flutamide for a mean of 13.8 months. The histological changes noted included severe generalized atrophy of the seminiferous tubules, prominent degeneration of the Sertoli cells, with ultimate total tubular hyalinization, partial Sertoli-cell-only syndrome in 50 per cent of the testes (number of germ cells less than or equal to 0.95 per tubule), and pronounced collagenization and fibrosis of the interstitium (50 per cent) with total atrophy of the Leydig cells in 92 per cent of the testes. These results show that the effect of prolonged high doses of buserelin in the majority of patients caused irreversible damage, particularly to spermatogenesis and the Sertoli cells, and thus to the intratesticular ultra-short loop. Therefore, when it is applied continuously in a high dose daily for a long period this drug does not appear to be suitable as a male contraceptive.
Collapse
Affiliation(s)
- F Hadziselimović
- Department of Urology, University Children's Hospital Basel, Switzerland
| | | | | |
Collapse
|
15
|
Weinbauer GF, Respondek M, Themann H, Nieschlag E. Reversibility of long-term effects of GnRH agonist administration on testicular histology and sperm production in the nonhuman primate. JOURNAL OF ANDROLOGY 1987; 8:319-29. [PMID: 2959641 DOI: 10.1002/j.1939-4640.1987.tb00970.x] [Citation(s) in RCA: 26] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
The present investigation evaluates the long-term effects of GnRH agonist treatment on testicular histology, sperm production and the subsequent recovery of these parameters. Four adult rhesus monkeys (M. mulatta) were treated with the GnRH agonist nafarelin (D-Nal(2)6-GnRH), released from i.m.--injected poly-D,L-lactic-co-glycolide microspheres for 20 months. Monthly injection of the GnRH agonist preparation uniformly suppressed serum levels of bioactive LH and testosterone. The size of the testis was reduced to about 30% of pretreatment. Sperm counts were suppressed to azoospermia for a total period of 53 and 77 weeks, respectively, in two monkeys and the other two animals were extremely oligozoospermic. Evaluation of testicular biopsy material after 6, 12 and 20 months of treatment revealed decreased seminiferous tubule diameter, spermatogenic disruption at the level of spermatogonia or spermatocytes, accumulation of lipid droplets and secondary lysosomes in the Sertoli cell cytoplasm, and increased thickness of the tubular wall compared with pretreatment histology. Electron microscopic examination revealed that the increased wall thickness was due to an enlargement of the inner collagen layer. No evidence of fibrosis or calcification could be obtained. Leydig cells were atrophic. Serum hormones, testis size and sperm counts returned to pretreatment values within 5 to 8, 13 to 16, and 18 weeks, respectively, after termination of treatment. Testicular histology, assessed 8 months after cessation of treatment, was indistinguishable from pretreatment. It is concluded that GnRH agonist-containing microspheres are a feasible modality for sustained administration of GnRH agonists and GnRH agonist-induced suppression of pituitary and testicular function is reversible following withdrawal of treatment. Thus, GnRH agonists may have a potential for regulation of male fertility and, presumably, also for treatment of precocious puberty.
Collapse
Affiliation(s)
- G F Weinbauer
- Max Planck Clinical Research Unit for Reproductive Medicine, University of Münster, Federal Republic of Germany
| | | | | | | |
Collapse
|
16
|
Petersson F, Hammar M, Mathson K, Hjertberg H, Varenhorst E. Influence of continuous luteinizing hormone-releasing hormone agonist treatment on steroidogenic enzymes in the human testis. SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY 1987; 21:267-71. [PMID: 2965409 DOI: 10.3109/00365598709180780] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Nine elderly men with prostatic carcinoma underwent treatment with a LHRH-agonist (Zoladex, ICI) for 3-6 months. At the end of the treatment period the patients underwent subcapsular orchidectomy. Testicular tissue was incubated with different tritiated testosterone precursors. Conversion mediated by several testicular steroidogenic enzymes was compared between Zoladex-treated patients and nineteen non-treated patients who underwent orchidectomy because of prostatic carcinoma. Serum concentrations of LH, FSH and testosterone were determined before and during treatment in the treated patients. The LHRH agonist treatment induced significantly decreased conversion mediated by the enzymes 3 beta-hydroxysteroid dehydrogenase, 17 alpha-hydroxylase and C17-20 lyase. Conversion mediated by 17 beta-ketosteroid reductase was also decreased although not as dramatically as the other enzymes, while conversion mediated by 20 alpha-dehydrogenase was increased. Serum concentrations of testosterone decreased to castration levels. Serum gonadotrophins decreased but remained within normal levels suggesting that "desensitization" at the pituitary level was not the only mechanism of action of the LHRH-agonist.
Collapse
Affiliation(s)
- F Petersson
- Department of Obstetrics and Gynaecology, University Hospital of Linköping, Sweden
| | | | | | | | | |
Collapse
|
17
|
Wojciechowski NJ, Carter CA, Skoutakis VA, Bess DT, Falbe WJ, Mickle TR. Leuprolide: a gonadotropin-releasing hormone analog for the palliative treatment of prostatic cancer. DRUG INTELLIGENCE & CLINICAL PHARMACY 1986; 20:746-51. [PMID: 2429815 DOI: 10.1177/106002808602001001] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Leuprolide is the first member of the class of gonadotropin-releasing hormone (GnRH) agonist analog to be released in the U.S. The pharmacology of leuprolide is complex and not yet completely defined. This agonist analog is more potent than natural GnRH and appears to be capable of occupying pituitary GnRH receptors. This results in a "down regulation" of the receptors' activity and gonadotropin release, ultimately decreasing serum testosterone levels to those seen following castration. Leuprolide has been found effective in the palliative treatment of advanced cases of prostatic cancer and is not associated with the cardiovascular and thromboembolic toxicity seen with conventional diethylstilbestrol therapy. Leuprolide is administered by daily subcutaneous injections and has been generally well tolerated. The most common adverse effects are hot flashes and a possible flare-up of prostatic carcinoma symptoms on initial dosing. As clinical experience grows in the use of GnRH agonist analog, GnRH will assume a greater role in the treatment of metastatic prostatic cancer.
Collapse
|
18
|
|
19
|
|
20
|
Rajfer J, Handelsman DJ, Swerdloff RS, Hurwitz R, Kaplan H, Vandergast T, Ehrlich RM. Hormonal therapy of cryptorchidism. A randomized, double-blind study comparing human chorionic gonadotropin and gonadotropin-releasing hormone. N Engl J Med 1986; 314:466-70. [PMID: 2868413 DOI: 10.1056/nejm198602203140802] [Citation(s) in RCA: 105] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
We conducted a randomized, double-blind study comparing intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days) with parenteral human chorionic gonadotropin (3300 IU per week for four weeks) in the treatment of cryptorchidism in 33 boys one to five years old (29 with unilateral and 4 with bilateral cryptorchidism). Testicular descent into the scrotum occurred in 3 of the 16 patients (19 percent) treated with gonadotropin-releasing hormone and in 1 of the 17 (6 percent) treated with human chorionic gonadotropin (P = 0.23). The mean luteinizing hormone and testosterone levels were similar in both groups before treatment. During treatment, the testosterone levels were significantly increased in both groups, but higher levels occurred in the group treated with human chorionic gonadotropin (P less than 0.05). In a parallel (but uncontrolled) study of five boys with retractile testes (defined as a nonscrotal testis that could be manipulated into the bottom of the scrotum) who were originally excluded from the main protocol but were treated with the same regimen of human chorionic gonadotropin, descent into the scrotum occurred in all patients. We conclude that hormonal therapy with either gonadotropin-releasing hormone or human chorionic gonadotropin is, in most cases, ineffective in promoting testicular descent of true cryptorchid testes. However, short-term treatment with human chorionic gonadotropin is very effective in producing descent of retractile testes. These results suggest that the wide discrepancies in apparent efficacy in previous trials of hormonal therapy of cryptorchidism may have been due to inclusion in those studies of various proportions of patients with retractile testes.
Collapse
|